Dessai S B, Adrash D, Geetha M, Arvind S, Bipin J, Nayanar S, Sachin K, Biji M S, Balasubramanian S
Department of Surgical Oncology, Malabar Cancer Center, Kannur, Kerala, India.
Department of Radiation Oncology, Malabar Cancer Center, Kannur, Kerala, India.
Indian J Cancer. 2016 Jul-Sep;53(3):416-419. doi: 10.4103/0019-509X.200678.
An audit was planned to study the demographics, staging, treatment details, and outcomes of operable endometrial cancers.
All operable endometrial cancers treated between January 2009 and October 2014 were included in the study. The details regarding demographics, staging, surgical procedure, pathological staging, adjuvant treatment, and outcomes were extracted from the case records. Descriptive statistics was performed. The time-to-event analysis was done by Kaplan-Meier method. Univariate and multivariate analyses were done for disease-free survival (DFS) and overall survival (OS).
There were 55 patients with a median age of 59 years (35-73 years). The Eastern Cooperative Oncology Group performance status was 1 in 52 patients (94.5%) and 2 in 3 patients (5.5%). Forty-nine patients (89.1%) had disease restricted to endometrium while 6 patients (10.9%) had cervical involvement. The surgery done was Type I hysterectomy in 49 patients (89.1%), Type II in 5 patients (9.1%), and Type III in 1 patient (1.8%). Pelvic lymph node dissection was done in all patients while para-aortic (infrahilar) dissection was done in 48 patients (87.3%). The pathological stages were Stage IA in 19 patients, Stage IB in 15 patients, Stage II in 4 patients, Stage IIIA in 3 patients, Stage IIIB in 2 patients, Stage IIIC1 in 5 patients, Stage IIIC2 in 4 patients, and Stage IV in 3 patients. Grade 1 tumors were seen in 23 patients, Grade 2 in 13 patients, and Grade 3 in 19 patients. The histology was endometrioid in 44 patients, serous in 6 patients, clear cell in 3 patients, and others in 2 patients. Adjuvant treatment was received by 40 patients. With a median follow-up of 2.5 years, the 3-year DFS and OS were 78% and 82%, respectively. Age >59 years, Stage III or greater, and Grade 3 tumors were independent prognostic factors adversely affecting both DFS and OS.
The outcomes in our study are comparable to that seen in Western literature. Elderly status, higher stage, and a poorly differentiated tumor are associated with poor outcomes.
计划进行一项审计研究,以了解可手术治疗的子宫内膜癌的人口统计学特征、分期、治疗细节及预后情况。
本研究纳入了2009年1月至2014年10月期间接受手术治疗的所有可手术切除的子宫内膜癌患者。从病例记录中提取有关人口统计学、分期、手术程序、病理分期、辅助治疗及预后的详细信息。进行描述性统计分析。采用Kaplan-Meier法进行生存时间分析。对无病生存期(DFS)和总生存期(OS)进行单因素和多因素分析。
共55例患者,中位年龄59岁(35 - 73岁)。东部肿瘤协作组(Eastern Cooperative Oncology Group)体能状态评分为1分的患者有52例(94.5%),评分为2分的患者有3例(5.5%)。49例患者(89.1%)疾病局限于子宫内膜,6例患者(10.9%)有宫颈受累。49例患者(89.1%)行I型子宫切除术,5例患者(9.1%)行II型子宫切除术,1例患者(1.8%)行III型子宫切除术。所有患者均行盆腔淋巴结清扫术,48例患者(87.3%)行腹主动脉旁(肾门以下)淋巴结清扫术。病理分期为IA期19例,IB期15例,II期4例,IIIA期3例,IIIB期2例,IIIC1期5例,IIIC2期4例,IV期3例。23例患者为1级肿瘤,13例患者为2级肿瘤,19例患者为3级肿瘤。组织学类型为子宫内膜样癌44例,浆液性癌6例,透明细胞癌3例,其他类型2例。40例患者接受了辅助治疗。中位随访时间为2.5年,3年DFS和OS分别为78%和82%。年龄>59岁、III期或更高分期以及3级肿瘤是对DFS和OS均有不利影响的独立预后因素。
我们研究中的预后情况与西方文献报道的相当。老年状态、较高分期以及低分化肿瘤与不良预后相关。